SETH LERNER to Pyrimidines
This is a "connection" page, showing publications SETH LERNER has written about Pyrimidines.
Connection Strength
0.110
-
Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling. Mol Cancer Ther. 2010 May; 9(5):1128-35.
Score: 0.070
-
Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. Future Oncol. 2022 Jul; 18(21):2599-2614.
Score: 0.040